Valuation: bioMérieux

Market Cap 10.75B 11.8B 9.9B 9.01B 16.9B 1,092B 17.76B 121B 47.89B 597B 44.26B 43.33B 1,873B P/E 2026 *
21.3x
P/E 2027 * 20.2x
Enterprise Value 10.34B 11.35B 9.52B 8.66B 16.25B 1,051B 17.08B 116B 46.07B 574B 42.58B 41.68B 1,801B EV / Sales 2026 *
2.49x
EV / Sales 2027 * 2.28x
Free-Float
33.22%
Yield 2026 *
1.16%
Yield 2027 * 1.21%
Manager TitleAgeSince
Chief Executive Officer 54 30/06/2023
Director of Finance/CFO 50 28/02/2018
Chief Tech/Sci/R&D Officer - 31/07/2022
Director TitleAgeSince
Chairman 51 14/12/2017
Director/Board Member 67 31/12/2004
Director/Board Member 61 29/05/2012
Change 5-day change 1-year change 3-year change Capi.($)
-0.27%+1.25% - - 11.8B
-0.84%-5.09%-19.60%+1.07% 178B
-0.67%-2.84%-1.25%+27.12% 122B
-0.98%+0.12%-15.82%+5.56% 118B
-1.24%-4.25%-42.94%-1.34% 88.1B
-0.63%-5.55%-7.27%+70.54% 64.71B
+0.05%-2.41%+10.41%-9.90% 57.96B
-1.95%-3.98%-6.85%+41.55% 53.28B
-2.91%-4.35%-0.97%+38.45% 47.8B
-1.64%+1.50%+1.30%-2.04% 35.65B
Average -1.11%-2.63%-9.22%+19.00% 85B
Weighted average by Cap. -1.03%-2.97%-12.44%+15.68%

Financials

2026 *2027 *
Net sales 4.16B 4.57B 3.83B 3.49B 6.54B 423B 6.87B 46.64B 18.54B 231B 17.13B 16.77B 725B 4.39B 4.82B 4.04B 3.68B 6.9B 446B 7.25B 49.18B 19.55B 244B 18.07B 17.69B 764B
Net income 507M 557M 467M 425M 797M 51.54B 838M 5.69B 2.26B 28.15B 2.09B 2.04B 88.36B 536M 589M 494M 449M 843M 54.5B 886M 6.01B 2.39B 29.77B 2.21B 2.16B 93.42B
Net Debt -409M -449M -377M -343M -643M -41.6B -676M -4.59B -1.82B -22.72B -1.69B -1.65B -71.31B -727M -799M -670M -610M -1.14B -73.96B -1.2B -8.16B -3.24B -40.4B -3B -2.93B -127B
Logo bioMérieux
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.3%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.7%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East /Africa (32.3%), North America (45.4%), Asia/Pacific (15.6%), and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - bioMérieux